# EDGAR Filing Document

**Accession Number:** 0001133818
**File Stem:** 0000000000-26-003337
**Filing Date:** 2026-4
**Character Count:** 2755
**Document Hash:** 47676f0f2a1b99362e8ab50f2376d9b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-003337.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0000000000-26-003337

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260401

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-PATH HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001133818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870652870
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 024-12728

**BUSINESS ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401
- **BUSINESS PHONE:** (832) 742-1357

**MAIL ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO-PATH HOLDINGS INC
- **DATE OF NAME CHANGE:** 20080221

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OGDEN GOLF CO CORP
- **DATE OF NAME CHANGE:** 20010205
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001663577-26-000075

## Text-Extract

```

                                                             April 1, 2026

Vikram Grover
Chief Executive Officer
BioPath Holdings, Inc.
625 Stanwix St. #2407
Pittsburgh, PA 15222

        Re: BioPath Holdings, Inc.
            Offering Statement on Form 1-A
            Filed March 25, 2026
            File No. 024-12728
Dear Vikram Grover:

       This is to advise you that we do not intend to review your offering
statement.

        We will consider qualifying your offering statement at your request. In
connection with
your request, please confirm in writing that at least one state has advised you
that it is prepared
to qualify or register your offering. If a participant in your offering is
required to clear its
compensation arrangements with FINRA, please have FINRA advise us that it has
no objections
to the compensation arrangements prior to qualification.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Please contact Lauren Hamill at 303-844-1008 with any questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:    Sean Doney

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._